VECATA

Vecata Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for neurodevelopmental and neuropsychiatric disorders. The company's lead program, VCT-001, is a proprietary formulation of acamprosate being developed for the treatment of Fragile X Syndrome and Autism Spectrum Disorder. Vecata's therapeutic approach targets the imbalance between excitatory and inhibitory neurotransmission, specifically modulating GABAergic and glutamatergic pathways to address core behavioral and cognitive symptoms. The company was established as a successor to Confluence Pharmaceuticals to advance these programs through mid-to-late-stage clinical development. Vecata aims to provide life-changing therapies for patients with significant unmet needs in the neurodevelopmental space.